New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
“Given the long-term success of Humira, which can cost patients up to $84,000 a year, initial uptake of the biosimilars may be limited, said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors.”
A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.
MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”
MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”